Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 15/20 | 0.67 |
| ▸ | MMP2 | P08253 | 15/20 | 0.67 |
| ▸ | MMP9 | P14780 | 15/20 | 0.67 |
| ▸ | MAOB | P27338 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458024 | 1.00 | MMP1 (0.67) | MMP1MMP2MMP9MAOB | |
| SCHEMBL12425741 | 0.84 | HDAC2 (0.69) | MMP1MMP2MMP9MAOB | |
| SCHEMBL14244489 | 0.84 | HDAC2 (0.69) | MMP1MMP2MMP9MAOB | |
| SCHEMBL5250765 | 0.83 | NPSR1 (0.67) | MMP1MMP2MMP9MAOB | |
| SCHEMBL5250768 | 0.83 | NPSR1 (0.67) | MMP1MMP2MMP9MAOB | |
| SCHEMBL28294355 | 0.81 | CA12 (0.59) | MMP1MMP2MMP9MAOB | |
| SCHEMBL28872986 | 0.81 | MMP1 (0.57) | MMP1MMP2MMP9MAOB | |
| SCHEMBL457838 | 0.81 | MMP1 (0.60) | MMP1MMP2MMP9MAOB | |
| SCHEMBL457714 | 0.81 | MMP1 (0.61) | MMP1MMP2MMP9MAOB | |
| SCHEMBL31019567 | 0.81 | MMP1 (0.61) | MMP1MMP2MMP9MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853276-B2 | Guanidine derivatives in cinnamic series | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2014-10-07 | — | — | US | disclosed |
| EP-2614046-B1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | PROD CHIM AUXILIAIRES ET DE SYNTHESE (FR) | 2014-08-20 | — | — | EP | disclosed |
| EP-2614046-A1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | Produits Chimiques Auxiliaires et de Synthese (FR) | 2013-07-17 | — | — | EP | disclosed |
| US-20130165507-A1 | NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2013-06-27 | — | — | US | disclosed |
| WO-2012032257-A1 | NOVEL GUANIDINE DERIVATIVES IN THE CINNAMIC SERIES | PRODUITS CHIMIQUES AUXILIAIRES ET DE SYNTHESE (FR) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165507-A1 | NEW GUANIDINE DERIVATIVES IN CINNAMIC SERIES | GMPS, UNG, AGER | MMP1 1696/4885MMP2 1516/4885MMP9 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.